- Therapeutic Cataract & Refractive
- Lens Technology
- Glasses
- Ptosis
- Comprehensive Eye Exams
- AMD
- COVID-19
- DME
- Ocular Surface Disease
- Optic Relief
- Geographic Atrophy
- Cornea
- Conjunctivitis
- LASIK
- Myopia
- Presbyopia
- Allergy
- Nutrition
- Pediatrics
- Retina
- Cataract
- Contact Lenses
- Lid and Lash
- Dry Eye
- Glaucoma
- Refractive Surgery
- Comanagement
- Blepharitis
- OCT
- Patient Care
- Diabetic Eye Disease
- Technology
What happened in optometry this week: April 22 - April 26
Catch up on what happened in optometry during the week of April 22-April 26.
Catch up with what Optometry Times shared this week:
Ocugen completes dosing of subjects with GA in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410
By David Hutton, Managing Editor, Ophthalmology Times
Ocugen Inc announced dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD).1
Study reports statistically significant improvements of DED symptoms with Bausch + Lomb’s LCD supplement
By Jordana Joy, Associate Editor
Bausch and Lomb announced that its proprietary blend of lutein, zeaxanthin isomers, curcumin, and vitamin D3 (LCD) received statistically significant results from a clinical study published in Frontiers in Ophthalmology, according to a news release. The prospective, randomized, double-blind, parallel, placebo-controlled study evaluated the efficacy and safety of the novel daily nutritional supplement formulated to address the symptoms of dry eye disease (DED). The primary endpoints were the change in tear production and participant reports of DED symptoms at day 56 of the trial.1
Fact or fiction? A closer look at management options
By Michael Chaglasian, OD, FAAO, and Barbara M. Wirostko, MD, FARVO
Glaucoma is a slowly progressive optic neuropathy and a leading cause of irreversible blindness worldwide. Findings from our progressive longitudinal studies have demonstrated that a leading risk factor is a number, the intraocular pressure (IOP). We use this number to diagnose, treat, manage, and change therapies, including surgical recommendations. However, we only collect a single number at a single time point and, in many instances, only once every 3 to 6 months. IOP fluctuates and is a volatile and dynamic number that is often higher in the early waking hours.1
The Myopia Collective: AOA, CooperVision unveil exciting new collaboration
By Michele Andrews, OD; Terri A. Gossard, OD, MS; and Emily Kaiser Maharjan, Assistant Managing Editor
Earlier this week, the American Optometric Association (AOA) and CooperVision revealed a partnership called The Myopia Collective to improve the standard of care for patients with myopia. For years, optometrists have aimed to correct myopia, but The Myopia Collective believe its time to embrace comprehensive treatment of the disease.
Michele Andrews, OD, vice president of professional and government affairs for CooperVision, and Terri A. Gossard, OD, MS, member of the AOA board of trustees, sat down with Optometry Times to discuss the goals and tactics of The Myopia Collective.
WVU Medicine planning expansion, relocation of WVU Eye Institute
By David Hutton, Managing Editor, Ophthalmology Times
The West Virginia Eye Institute announced it will expand its clinical, educational, and research efforts when it moves into a new location in Morgantown.
According to a university news release, the WVU Health System Board of Directors approved $233.5 million to fund the construction of a multi-center outpatient facility. It will also include a multi-level parking garage with more than 1,100 spaces.1
